POSTER SESSION VI
Wednesday, March 24, 2010 — 1:00 PM - 4:00 PM
Exhibit Hall
Click on the blue numbers in parentheses to display abstracts.
Click the button next to any title to add to Itinerary Planner...
GYNECOLOGIC PATHOLOGY
Poster#
Title and Authors
Itinerary Planner
150
WITHDRAWN
151
Differential Genome-Wide DNA Methylation Patterns between Low Grade and High Grade Papillary Serous Carcinoma of the Ovary
(1194)
A Ting, B Yang - Cleveland Clinic, Cleveland, OH
Identification of a mRNA Protease Profile Associated with Early Relapse in Serous Ovarian Cancer
(1197)
D Trudel, I Bairati, CM Overall, R Kappelhoff, M Plante, B Tetu - Centre Hospitalier Universitaire de Quebec, Quebec, Canada; University of British Columbia, Vancouver, Canada
Between-Site Variability in Immune Response to Metastatic Serous Ovarian Carcinoma
(1096)
IS Hagemann, AR Hagemann, P Lal, G Coukos, MD Feldman - University of Pennsylvania, Philadelphia, PA
Pathological Diagnosis of Grade in Primary Mucinous Ovarian Tumor
(1202)
K Wakasa, T Wakasa, M Ohsawa - Osaka City University Graduate School of Medicine, Osaka, Japan; Osaka Red Cross Hospital, Osaka, Japan
Hypoxia-Inducible Factor and Mammalian Target of Rapamycin Pathway Markers in Ovarian Clear Cell Carcinoma
(1098)
G Han, RA Soslow, VE Reuter, E Oliva, CB Gilks, H Asad, SK Tickoo - Memorial Sloan-Kettering Cancer Center, New York; Massachusetts General Hospital, Boston; Vancouver General Hospital, Vancouver, Canada
Ovarian Clear Cell Carcinomas: RHO GTPases May Explain Their Singular Biologic Behavior
(1054)
B Canet, ML Romero, I Espinosa, J Pena, J Prat - Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain
The Molecular Profile of Ovarian Transitional Cell Carcinoma
(1135)
TL Mao, MI Hsieh, KT Kuo, MC Lin - National Taiwan University Hospital, Taipei, Taiwan
Immunohistochemical Classification of the 5 Major Subtypes of Ovarian Carcinoma and the Introduction of the Calculator for Ovarian Subtype Prediction
(1111)
SE Kalloger, M Kobel, S Leung, E Mehl, D Gao, K Masson, DG Huntsman, CB Gilks - Vancouver General Hospital and the British Columbia Cancer Agency, Vancouver, BC, Canada; University of Calgary/CLS, Calgary, AB, Canada
Immunohistochemical Study of DNA Repair Related Proteins in Sporadic Ovarian Cancer
(1056)
J Castellvi, A Garcia, A Perez-Benavente, MC Ruiz-Marcellan, F Marginean, D Badia, C Parada, S Ramon y Cajal - Vall de Hebron Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
Androgen Receptor Coactivator p44/Mep50 in Ovarian Cancer
(1154)
LY Pan, JJ Wei, RR Patwa, M Ligr, S Jain, XY Zou, G Daniels, YR Li, RL Xu, W Sun, ZX Wang, P Lee, F Chen - New York University, New York, NY; NY Harbor, New York, NY; MD Anderson, Houston, TX
GADD45a Protein Expression in Endometrial and Ovarian Tumors
(1182)
EA Slodkowsak, J Torres-Mora, CE Sheehan, JS Ross - Albany Medical College, Albany, NY
Overexpression of Clusterin Is Predictive of Aggressive Biology of Primary Ovarian Cancer
(1208)
GF Yang, D Xie, Y Liu, YR Lia, WP He, B Fu, CY Fan - The First Affiliated Hospital, Sun Yat-Sen Univ Med Sciences, Guangzhou, China; Cancer Center, Sun Yat-Sen Univ Med Sciences, Guangzhou, China; Guangdong Specialty Hospital of Fertility, Guangzhou, China; Xu Wen Hospitail of Traditional Chinese Medicine, Zhanjiang, Guangdong, China; John L McClellan Memorial Veterans Hospital and UAMS, Little Rock, AR
Functional Expression Analysis of TLR-4 and MYD88 in Epithelial Ovarian Neoplasia
(1069)
CJ d'Adhemar, MF Gallagher, S O'Toole, C Murphy, PC Smyth, C Martin, O Sheils, JJ O'Leary - Trinity College Dublin, Dublin, Ireland; Coombe Women's Hospital, Dublin, Ireland
Genome-Wide Copy Number Alteration Profiles in Various Ovarian Carcinomas
(1136)
TL Mao, HL Kao, JJ Sheu, KT Kuo - National Taiwan University Hospital, Taipei, Taiwan; Graduate Institute of Chinese Medical Science, Taichung, Taiwan
Examining the Relationship between Expression of Selected Tumour Associated Genes, Platelet Count and Survival in Ovarian Cancer
(1067)
DJ Crowley, RJ Flavin, SA O'Toole, ST Aherne, PC Smyth, K Egan, E Dunne, D Kenny, JJ O'Leary, OM Sheils - Institute of Molecular Medicine, Trinity College Dublin, Dublin, Ireland; Harvard Medical School, Boston, MA; Trinity Centre for Health Sciences, Trinity College Dublin and Royal College of Surgeons, Dublin, Ireland
Epigenetic Inactivation of Clusterin Gene May Predict for Mesenteric Metastasis of Primary Ovarian Cancer
(1163)
CM Quick, HH Zhang, GF Yang, CY Fan - University of Arkansas for Medical Sciences, Little Rock, AR; John L McClellan Memorial Veterans Hospital and UAMS, Little Rock, AR; The First Affiliated Hospital, Sun Yat-Sen Univ Med Sciences, Guangzhou, China
The Utility of Circulating Tumor Cells in Monitoring Patients with Recurrent Ovarian Cancer
(1117)
DW Kindelberger, U Matulonis - Brigham and Women's Hospital, Boston, MA; Dana-Farber Cancer Institute, Boston, MA
Immunolocalisation of Key Spindle Assembly Checkpoint Proteins - Correlation with Cellular Prolifaration and Chemotherapeutic Response
(1160)
SM Phelan, B McGrogan, M Prencipe, P Fitzpatrick, D Brennan, C O'Herlihy, M Foley, E Doyle, J Harford, T O'Grady, E Kay - University College Dublin; National Maternity Hospital; St. Vincent's University Hosptial; Royal College of Surgeons in Ireland, Dublin, Ireland
The Role of HuR in Gemcitabine Efficacy in Ovarian Cancer
(1166)
W Rizzo, R Gogoi, C Constantino, J Sawicki, J Brody, A Witkiewicz - Thomas Jefferson University Hospital, Philadelphia, PA; Lankenau Institute for Medical Research, Wynnewood, PA
Natural History of Biologically Malignant Struma Ovarii: Analysis of 27 Cases with Extra-Ovarian Spread
(1175)
R Shaco-Levy, SM Bean, RC Bentley, SJ Robboy - Soroka Medical Center, Beer-Sheva, Israel; Duke University Medical Center, Durham, NC
Omental Icing: An Unusual Variant of Peritoneal Carcinomatosis Due to Metastatic Gastric or Breast Cancer
(1110)
CA Jimenez, JT Rabban - UCSF, San Francisco, CA
Diagnostic Markers in the Differentiation of Gynecologic and Urological Clear Cell Carcinoma
(1205)
RJ Wolsky, E Lengyel, AG Montag - University of Chicago, Chicago
The Utility of PAX8 in Patients with Both Breast and Mullerian Carcinomas
(1080)
ED Euscher, MT Deavers - The University of Texas MD Anderson Cancer Center, Houston, TX
PAX8 Distinguishes Serous Ovarian Neoplasms from Malignant Mesothelioma with High Sensitivity and Specificity
(1125)
AR Laury, JL Hornick, JM Corson, JF Krane, R Drapkin, MS Hirsch - Brigham and Womens Hospital, Boston, MA; Dana Farber Cancer Institute, Boston, MA
PAX2, a Sensitive and Specific " Negative" Marker To Differentiate Diffuse Malignant Mesotheliomas of Peritoneum from Serous Carcinomas of Mullerian Origin
(1088)
FF Gao, AM Krasinskas, M Chivukula - University of Pittsburgh Medical Center and Magee-Women's Hospital, Pittsburgh, PA
Mammaglobin Expression in Primary Ovarian Carcinoma and Its Utility in the Differential Diagnosis of Metastatic Mammary Carcinoma to Ovary
(1190)
Y Sun, P Newcomb, D Mandich, R Cartun, S Mandavilli - Hartford Hospital, Hartford, CT
A Tissue Microarray Immunohistochemical Study of Gynecologic Versus Breast Primary
(1159)
TC Pereira, SM Share, KM Jasnosz, AV Magalhaes, JF Silverman - Allegheny General Hospital, Pittsburgh, PA; Universidade de Brasilia, Brasilia, Brazil
button next to any title to add to Itinerary Planner...
Add
